Metabolic Bone Disease/ Musculoskeletal Oncology Service The Metabolic Bone Disease/ Musculoskeletal Oncology Service is focused on the prevention and treatment of osteoporosis and related bone disorders, including fragility fractures. It unites practitioners from multiple disciplines, including orthopaedics, rheumatology, physiatry, endocrinology, nephrology and pediatrics. CHIEF Joseph M. Lane, MD
Clinical Highlights In 2015, we developed and improved our Fracture Liaison Service, championed by Joseph Lane, MD. As one of only a few institutions in the country to endorse this program as a standard of care, we have been able to provide our patients with the highest quality care available. In this program, a team of Nurse Practitioners, Registered Nurses and PGY1 Residents performs in-house metabolic bone disease consultations on all patients who have suffered a fragility fracture or are at risk for osteoporosis at both HSS and NewYork-Presbyterian/ Weill Cornell Medical Center. Patients are worked up, then referred to the appropriate providers to ensure their underlying bone disease is addressed. The goal is to prevent a future fracture. We have performed a retrospective, as well as prospective, review of the data to better understand the strengths and weaknesses of the program. Currently, we are expanding the program to include osteoporosis patients who are having orthopaedic procedures. Emily Stein, MD, joined our Metabolic Bone Disease Team in 2016. She is an
expert in clinical trials and bone mass evaluation. Dr. Stein trained at Weill Cornell Medical College/Memorial Sloan-Kettering Cancer Center and NewYork-Presbyterian/Columbia.
Research Initiatives The Service is investigating the effects of bisphosphonate treatment on the development of a transverse, atypical femoral fracture. The Service received funding from the National Institutes of Health to determine if administering a key component of the PTH hormone (amino acids 1–34) will help increase bone density and strength in patients who have had a pelvic fracture. The Service will use validated questionnaires to measure factors such as walking speed and grip strength to determine frailty. Our investigators will then determine which bones patients have fractured, such as the hip, ankle, wrist or pelvis, and look for correlations with their frailty.
FROM LEFT TO RIGHT: Joseph M. Lane, MD; Juliet B. Aizer, MD, MPH; Panagiota Andreopoulou, MD; Richard S. Bockman, MD, PhD; Adele L. Boskey, PhD; Azeez M. Farooki, MD; Marci Anne Goolsby, MD; Linda A. Russell, MD; Robert Schneider, MD; Alana C. Serota, MD; Emily Stein, MD
26